Laser texturing of a St. Jude Medical RegentTM mechanical heart valve prosthesis: the proof of concept.

OBJECTIVES: The liquid-solid interactions have attracted broad interest since solid surfaces can either repel or attract fluids, configuring a wide spectrum of wetting states (from superhydrophilicity to superhydrophobicity). Since the blood-artificial surface interaction of bileaflet mechanical heart valves essentially represents a liquid-solid interaction, we analysed the thrombogenicity of mechanical heart valve prostheses from innovative perspectives. The aim of the present study was to modify the surface wettability of standard St. Jude Medical Regent™ occluders. METHODS: Four pyrolytic carbon occluders were irradiated by means of ultra-short pulse laser, to create 4 different nanotextures (A-D), the essential prerequisite to achieve superhydrophobicity. The static surface wettability of the occluders was qualified by the contact angle (θ) of 2 µl of purified water, using the sessile drop technique. The angle formed between the liquid-solid and the liquid-vapour interface was the contact angle and was obtained by analysing the droplet images captured by a camera. The morphology of the occluders was characterized and analysed by a scanning electron microscope at different magnifications. RESULTS: The scanning electron microscope analysis of the textures revealed 2 different configurations of the pillars since A and B showed well-rounded shaped tops and C and D flat tops. The measured highest contact angles were comprised between 108.1° and 112.7°, reflecting an improved hydrophobicity of the occluders. All the textures exhibited, to different extents, an orientation (horizontal or vertical), which was strictly related to the observed anisotropy. CONCLUSIONS: In this very early phase of our research, we were able to demonstrate that the intrinsic wettability of pyrolytic carbon occluders can be permanently modified, increasing the water repellency.

Characterization of circulating tumor cells by fluorescence in situ hybridization.

Tumor cells in blood of patients with metastatic carcinomas have been associated with poor survival prospects. Further characterization of these cells may provide further insights into the metastatic process. Circulating Tumor Cells (CTC) were enumerated in 7.5 mL of blood with the CellSearch system. After enumeration of Cytokeratin+, CD45-, nucleated cells, the cells are fixed in the cartridge while maintaining their original position. Cartridges were hybridized with FISH probes against the centromeric regions of chromosome 1, 7, 8, and 17. Next fluorescence images of the FISH probes of the previous identified CTC were acquired. Leukocytes surrounding the CTC were used as internal controls. The number of copies of chromosome 1, 7, 8, and 17 could be determined in 118 CTC containing blood samples from 59 metastatic prostate cancer patients. The samples contained a total of 21,751 CTC (mean 184, median 16, SD 650). Chromosome counts were obtained in 61% of the relocated CTC. On an average, these CTC contained 2.8 copies of chromosome 1, 2.7 copies of chromosome 7, 3.1 copies of chromosome 8, and 2.3 copies of chromosome 17. CTC in which no chromosome count was obtained most likely underwent apoptosis indicated by the expression of M30. In 6/59 patients only diploid CTC were detected these samples, however, only contained 1-5 CTC. Heterogeneity in the chromosomal abnormalities was observed between CTC of different patients as well as among CTC of the same patient. Cytogenetic composition of CTC can be reliably assessed after they have been identified by the CellSearch system. The majority of CTC in hormone refractory prostate cancer are aneuploid confirming that they indeed are cancer cells. An extensive heterogeneity in the copy number of each of the chromosomes was observed.

Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer.

Hormone-driven expression of the ERG oncogene after fusion with TMPRSS2 occurs in 30% to 70% of therapy-naive prostate cancers. Its relevance in castration-resistant prostate cancer (CRPC) remains controversial as ERG is not expressed in some TMPRSS2-ERG androgen-independent xenograft models. However, unlike these models, CRPC patients have an increasing prostate-specific antigen, indicating active androgen receptor signaling. Here, we collected blood every month from 89 patients (54 chemotherapy-naive patients and 35 docetaxel-treated patients) treated in phase I/phase II clinical trials of an orally available, highly specific CYP17 inhibitor, abiraterone acetate, that ablates the synthesis of androgens and estrogens that drive TMPRSS2-ERG fusions. We isolated circulating tumor cells (CTC) by anti-epithelial cell adhesion molecule immunomagnetic selection followed by cytokeratin and CD45 immunofluorescence and 4',6-diamidino-2-phenylindole staining. We used multicolor fluorescence in situ hybridization to show that CRPC CTCs, metastases, and prostate tissue invariably had the same ERG gene status as therapy-naive tumors (n=31). We then used quantitative reverse transcription-PCR to show that ERG expression was maintained in CRPC. We also observed homogeneity in ERG gene rearrangement status in CTCs (n=48) in contrast to significant heterogeneity of AR copy number gain and PTEN loss, suggesting that rearrangement of ERG may be an earlier event in prostate carcinogenesis. We finally report a significant association between ERG rearrangements in therapy-naive tumors, CRPCs, and CTCs and magnitude of prostate-specific antigen decline (P=0.007) in CRPC patients treated with abiraterone acetate. These data confirm that CTCs are malignant in origin and indicate that hormone-regulated expression of ERG persists in CRPC.